FLNA:BMV
Filana Therapeutics Inc
MX$15.92
0.00%
(0.00) 1 天
10月5日, GMT-6 12:05:31 · MXN
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 FLNA 生成关键数据洞见…
市值
3402.04万
平均成交量
0.00
成交量
0.00
52 周最高价
MX$56.00
52 周最低价
MX$15.92
员工人数
19
市值
3402.04万
平均成交量
0.00
成交量
0.00
52 周最高价
MX$56.00
52 周最低价
MX$15.92
员工人数
19
新闻报道
来自网络来源和新闻合作伙伴
资料
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Filana Therapeutics Inc简介